Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages.
Hepatitis C virus (HCV) is the leading cause of chronic hepatitis, affecting approximately 2% of the world's population. The immune mechanisms responsible for the highly variable natural history in a given individual are unknown. We used a multiparameter flow cytometric technique to functionally and phenotypically characterize HCV-specific effector T cells in the peripheral blood of 32 individuals with different stages of hepatitis C disease (resolved, mild chronic, advanced chronic) and normal controls. We found the highest frequencies of virus-specific effector cells with an activated memory phenotype (CD45RO+CD69+) in subjects who had resolved HCV infection, either spontaneously or with antiviral therapy. Effector cells from patients with resolved infection produced Th1 type cytokines following stimulation with nonstructural antigens (NS3 and NS4), whereas effector cells from chronically infected patients produced Th1 type cytokines predominantly following stimulation with the HCV core antigen. Stimulation with superantigen staphylococcal enterotoxin (SEB) induced the same levels of cytokine production in the different patient groups. Among the HCV-seropositive patients, viral load inversely correlated with the Th1 effector cell response to NS3. Interleukin (IL)-4 was produced only in response to the control antigens, but not in response to the HCV recombinant proteins. Taken together, these findings suggest that a vigorous HCV-specific CD4+ Th1 response, particularly against the nonstructural proteins of the virus, may be associated with viral clearance and protection from disease progression. Prospective studies using this new flow cytometric assay will be required to determine whether antiviral therapy modifies the frequency, specificity, and function of these virus-specific effector cells.
Rosen
Hugo R
HR
Department of Medicine, Portland Veterans Affairs Medical Center/Oregon Health and Science University, Portland OR 97207, USA.
Miner
Camette
C
Sasaki
Anna W
AW
Lewinsohn
David M
DM
Conrad
Andrew J
AJ
Bakke
Antony
A
Bouwer
H G Archie
HG
Hinrichs
David J
DJ
D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D016207:Cytokines / Q000032:analysis; D005260:Female; D005434:Flow Cytometry; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology*; D006526:Hepatitis C / Q000276:immunology*; D018937:Hepatitis C Antibodies / Q000097:blood; D018936:Hepatitis C Antigens / Q000276:immunology; D006801:Humans; D016130:Immunophenotyping; D015847:Interleukin-4 / Q000096:biosynthesis; D037181:Lectins, C-Type; D017493:Leukocyte Common Antigens / Q000032:analysis; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000032:analysis; D018417:Th1 Cells / Q000276:immunology; D019562:Viral Load; D000099192:CD69 Antigens
D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D016207:Cytokines; D018937:Hepatitis C Antibodies; D018936:Hepatitis C Antigens; D015847:Interleukin-4; D037181:Lectins, C-Type; D017493:Leukocyte Common Antigens; D012367:RNA, Viral; D000099192:CD69 Antigens